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Abstract
In Europe, as in many other regions of the world, breast 
cancer is a major cause of suffering and death. Early detection 
of breast cancer by systematic mammography screening 
can find lesions for which treatment is more effective and 
generally more favourable for quality of life. Comprehensive 
quality assurance guidelines for breast cancer screening ba-
sed on mammography have been developed in the Europe 
Against Cancer programme with the aim of maximising 
screening benefits while minimising adverse effects, such 
as unnecessary examination or treatment resulting from 
false-positive screening tests.  The present report provides 
an overview of the European experience in developing and 
implementing quality assurance guidelines for breast cancer 
screening. It highlights implications relevant to those regions 
of the world in which the burden of breast cancer in the 
coming years will make population-based screening an option 
for cancer control.
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Resumen
En Europa, como en muchas otras regiones del mundo, el 
cáncer de mama es una causa importante de sufrimiento 
y muerte. La detección temprana del cáncer de mama a 
través de un programa de tamizaje organizado mediante la 
mamografía sirve para encontrar lesiones cuyo tratamiento 
es más efectivo y generalmente más favorable para la calidad 
de vida. En el programa Europa contra el Cáncer se han 
desarrollado guías integrales de garantía de calidad para el 
tamizaje del cáncer de mama basado en la mamografía, con el 
fin de maximizar los beneficios del tamizaje y minimizar sus 
efectos adversos, que pueden resultar en resultados falsos 
positivos. El presente trabajo ofrece una visión general de la 
experiencia europea en el desarrollo y aplicación de las guías 
de control de calidad para el tamizaje del cáncer de mama. En 
él se destacan las implicaciones relevantes para las regiones 
del mundo en las que la incidencia del cáncer de mama en 
los próximos años hará del tamizaje poblacional una opción 
para el control del cáncer.
Palabras clave: programa de tamizaje organizado; mamografía; 
cáncer de mama; control de calidad
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According to estimates based on the Globocan database,1 cancer of the breast is the most com-
mon cancer, and the most common cause of death 
from cancer in women worldwide (figure 1). De-
mographic trends indicate a continuing increase in 
this substantial public health problem, particularly 
in the world’s less developed regions.* Worldwide 
1.38 million new cases (23% of all cancers in women) 
and 458 000 deaths due to breast cancer (12.7% of all 
cancer deaths in women) were estimated in 2008. The 
estimated incidence and mortality in Europe in 2008 
was 424 755 cases and 128 770 deaths.
 Figure 2 shows the range of estimated age-stan-
dardised incidence and mortality rates by region of the 
World in 2008. Western Europe and Eastern Africa are 
the regions with the highest and lowest incidence (89.9 
and 19.3 cases per 100 000 women, respectively). South 
America and the Caribbean are in an intermediate range 
(44.3 and 39.1 cases per 100 000). Central America and 
most regions of Asia and Africa are in the moderate 
to low range of incidence (<40 cases per 100 000). All 
too frequently, however, regions with moderate to low 
incidence are saddled with mortality rates similar to 
or exceeding that of Western Europe (17.5 deaths per 
100 000 women). This applies, for example to: South-
ern, Western and Northern Africa (19.3, 18.9 and 17.8 
deaths per 100 000, respectively). The age-standardised 
mortality rates in South America and the Caribbean 
are somewhat lower (13.2 and 14.2 deaths per 100 000). 
Common to all of these regions is a much less favor-
able relationship between incidence and mortality 
(approximately 2:1 in the above regions in Africa, and 
* In the Globocan data base,1 “more developed” regions are defined 
as: all regions of Europe plus Northern America, Australia/ New 
Zealand and Japan. “Less developed” regions are defined as: all 
regions of Africa, Asia (excluding Japan), Latin America and the 
Caribbean, Melanesia, Micronesia and Polynesia. The definitions are 
intended for statistical convenience and do not necessarily express 
a judgment about the stage reached by a particular country or area 
in the development process (source United Nations).
Figure 2. Breast cancer incidence and mortality By 
region in 2008. estimated age-standardised rates 
(World) per 100,0001
Figure 1. most common cancers in Women WorldWide 
in 2008. estimated numBers oF cases and deaths1
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3:1 in South America and the Caribbean) compared to 
5:1 in Western Europe. This reflects substantially higher 
survival of breast cancer patients in Western Europe due 
to earlier diagnosis and more effective treatment.
 Table I shows the broader range of age-standardized 
incidence and mortality rates estimated on a national 
basis rather than by aggregating the numbers of cases 
and deaths for several countries at the level of world re-
gions. The highest breast cancer incidence is estimated in 
Belgium and metropolitan France. The lowest incidence 
is estimated in Bhutan and Mongolia. The highest breast 
cancer mortality is estimated in Barbados and Lebanon, 
the lowest in Mongolia and Samoa. The estimated rates 
of a number of other countries and the ratio of the age-
standardized incidence and mortality rates are shown 
for comparison. Except for Japan and the United States 
of America, the rates reveal substantial to moderate 
room for improvement in breast cancer survival in most 
of the countries outside Western Europe, as reflected in 
the lower ratios of incidence to mortality.
 Mammography (X-ray examination of the breasts) 
can detect breast cancer before the tumour is palpable and 
before it causes symptoms.2 Tumours detected and treated 
at an early stage are associated with a better survival rate 
than those detected symptomatically. Early diagnosis may 
permit breast-conserving surgery (Stage I disease), reduce 
the need for adjuvant therapy and decrease complica-
tions related to intensive treatment and recurrence.3-5 
A re-appraisal of the randomised controlled trials, 
conducted by a working group of experts convened 
by the International Agency for Research on Cancer 
in 2002, concluded that there is sufficient evidence for 
the efficacy of screening women aged 50–69 years by 
mammography as the sole screening modality in reduc-
ing mortality from breast cancer.6 A large randomized 
controlled trial in Shanghai did not find an impact of 
systematic training in self examination of the breast on 
breast cancer mortality.7 There is currently insufficient 
evidence from studies in high-resource countries to 
support the efficacy of clinical breast examination or 
the teaching of self-examination of the breast as a public 
health strategy to lower the number of breast cancer 
deaths in the population.2 These methods are being eval-
uated for screening in low-resource countries in which 
most patients currently present for treatment at very 
late stages.8 A study aiming to reduce the proportion of 
newly diagnosed advanced stage breast cancer from 80 
to 60% using breast awareness, breast self-examination, 
clinical breast examination and centralised assessment 
of abnormalities is currently underway in India.*
 Systematic early detection of breast cancer through 
mammography screening in countries and regions with 
sufficient resources, has the potential to lower current 
breast cancer mortality rates and to reduce the burden of 
the disease in the population.9 The potential harm caused 
by mammography includes the creation of unnecessary 
anxiety and morbidity, inappropriate economic cost 
and the use of ionizing radiation10-13 For these reasons, 
mammography screening can only be a viable option 
for cancer control when resources permit the strongest 
possible emphasis on quality assurance.11-13 Furthermore, 
the current or the projected future burden of disease must 
be high enough for screening of asymptomatic women to 
generate sufficient benefit to appropriately outweigh the 
cumulative harms of screening in the population.14
 Numerous countries have adopted regulations 
and guidelines on quality assurance of mammography 
screening.15 In the United States, the Mammography 
Quality Standards Act (MQSA) has made certification 
of mammography facilities mandatory.16 Comprehen-
sive multidisciplinary guidelines for quality assurance 
in breast cancer screening and diagnosis have been 
developed by experts and published by the Euro-
pean Commission.11,12,17 The present report outlines 
the methodology, scope and fundamental principles 
Table 1
Burden oF Breast cancer in selected countries. 
age-standardized (World) incidence and mortality 
rates per 100 000 Women1
Region/Country Incidence Mortality Incidence / Mortality
Belgium 109.4 21.0 5
France (metropolitan) 99.7 17.6 6
United States of America 76.0 14.7 5
Argentina 74.0 20.1 4
Barbados 74.0 29.2* 3
Lebanon 55.4 26.1 2
Japan 42.7 9.2 5
Brazil 42.3 12.3 3
Mexico 27.2 10.1 3
India 22.9 11.1 2
Samoa 22.7 1.0‡ -
China 21.6 5.7 4
Bhutan 8.0 4.4 1
Mongolia 8.0 3.4 2
* Highest estimated rate
‡ Lowest estimated rate
*R. Sankaranarayanan, personal communication, 4 August 2010.
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underpinning the standards and recommendations in 
the fourth edition of the European Guidelines for Qual-
ity Assurance in Breast Cancer Screening and Diagnosis 
that were published by the European Commission in 
2006.12 Furthermore, aspects of the European experi-
ence in implementing population-based breast cancer 
screening programmes are discussed below that appear 
to be relevant outside the EU. Due to the complexity of 
the screening process and the comprehensive scope of 
the European Guidelines, the present report, like any 
other synopsis (e.g. Perry et al.11) cannot substitute for 
consultation of the full guideline document.15 
European Guidelines for Quality
Assurance in Breast Cancer
Screening and Diagnosis 
The EU guidelines have been prepared by over 200 
authors and contributors participating in a multidisci-
plinary network involving all of the current 27 EU Mem-
ber States, for exchange of experience and international 
collaboration in piloting, implementing and evaluating 
population-based breast cancer screening programmes.* 
Persons active in the network projects, most of which 
have received co-funding from the Europe Against Can-
cer Programme and the EU Public Health programme, 
have included screening professionals and scientists 
(radiologists, radiographers, surgeons, gynaecologists, 
oncologists, radiotherapists, breast care nurses, psychol-
ogists, medical physicists, epidemiologists, programme 
planners and administrators and other screening staff) 
and interested health professionals, legislators and 
breast care advocates. Network participants also come 
from EU applicant countries as well as Iceland, Norway, 
Switzerland, Canada, Israel, and the United States. The 
involvement of the 12 new Member States that joined 
the EU in 2004 and 2006 and the additional EU applicant 
countries in development of the current Guideline edi-
tion was limited, but the  12 “new” EU Member States 
and the applicant countries have in the meantime been 
integrated into the continuous efforts to disseminate 
and to update the EU Guidelines. Although not all 
network members have provided written contributions, 
guideline drafts have been discussed, and final versions 
have been approved at network meetings attended by 
participants from all EU Member States.
 Drafting and review of the guideline chapters 
and the overall document was coordinated by a mul-
tidisciplinary editorial board highly experienced in 
population-based breast cancer screening in Europe. 
Since most of the authors, contributors and reviewers 
were recruited from network projects, the guidelines 
rely significantly on knowledge and experience gained 
in piloting, implementing and evaluating population-
based breast cancer screening programmes.
 Unlike the recent preparation of the new European 
Guidelines for Quality Assurance in Colorectal Cancer 
Screening,19,20 a formal process of evaluating evidence 
was not adopted for preparation of the current, fourth 
edition of the EU breast screening guidelines. Instead, 
the editorial board determined the topics to be covered 
in the fourth edition, recruited the chief authors of each 
chapter and advised them on the recommended scope 
and key issues to be covered, and reviewed and edited 
each chapter. Chapter manuscripts were only accepted 
for publication if the editorial board concluded that 
current best practice in breast cancer screening and 
the relevant literature had been adequately taken into 
account. The editors were also conscious of the im-
portance of raising and maintaining standards across 
the EU. While maintaining those standards that are of 
prime importance for mortality reduction, an equitable 
balance of best practice and performance indicators 
was sought that can be used across a wide spectrum 
of cultural and economic healthcare settings. Care was 
taken to avoid promotion of recent research findings 
before their putative benefit has been demonstrated in 
clinical practice.
 The current fourth edition of the multidisciplinary 
guidelines (figure 3) consists of approximately 400 pages 
of recommendations, standards and protocols divided 
into twelve chapters (table II).
 Given the length of the fourth edition, only a few 
aspects can be covered in the present article that il-
lustrate the scope of the content of the EU Guidelines, 
and the core principles on which they are based (tables 
III-IV-V). More extensive summaries of the fundamental 
points and principles that should support any quality 
screening or diagnostic service have been prepared by 
the multidisciplinary editorial board of the fourth edi-
tion of the EU guidelines. These overviews include a 
Summary Table of Key Performance Indicators.11,12
Public health orientation
Breast cancer screening is a public health intervention 
that aims to lower the burden of the disease in the 
* The European Breast Cancer Screening Network was initially 
established in 1988 as a network of breast cancer screening pilot 
projects receiving financial support under the first Action plan of 
the Europe Against Cancer programme.18 The network expanded 
over the years and in 2004 was consolidated with the other European 
Cancer Screening Networks in the European Cancer Network for 
screening and primary prevention.
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a direct health benefit from participation in screening. 
However, all of the participants are exposed to the risks 
of screening, even if only slight. It is therefore necessary 
to make every effort to minimize the cumulative risk of 
screening to the overall population while maximizing 
the benefit.2,11-13
Screening process
Achieving the potential benefit of cancer screening 
requires optimal quality at every step in the screening 
process (table III), beginning with information and in-
vitation of the women eligible to attend screening, and 
extending from performance of the screening test to the 
diagnostic assessment of women with suspicious test re-
sults and, if necessary, treatment of women with screen-
detected lesions.2,11-13 In practice, the screening process 
is more complex than the schematic representation in 
table III. For example, the treatment phase includes not 
only clinical management of breast lesions but also re-
habilitation of breast cancer patients and palliative care 
if necessary. The standards, protocols, procedures and 
other recommendations in the EU Guidelines therefore 
aim to optimize and continuously improve quality and 
performance at each step in this process, including for, 
example, not only taking and reading mammograms, 
but also all aspects of physico-technical quality control, 
and multidisciplinary team working in the diagnosis 
and management of breast lesions (tables II and IV). 
Population-based approach
Comprehensive quality assurance is also required to 
maintain an appropriate balance between benefit and 
harm in the large numbers of women eligible to attend 
cancer screening programmes.11-13,21 Achieving and 
maintaining high quality at every step in the screening 
process requires an integrated, population-based ap-
proach to health service delivery, with personal invita-
tion of each eligible person in the target population.11,12,21 
Individual identification and invitation gives each 
eligible person an equal chance to benefit from screen-
ing and therefore reduces health inequalities.14,20,21 
Table II
chapters in 4th edition oF eu crc screening 
quality assurance guidelines For Breast cancer5
1. Epidemiology
2. Quality control of the physico-technical aspects of  mammography 
screening (screen-film and digital)
3. Radiography 
4. Radiology
5. Multi-disciplinary aspects of quality assurance in the  diagnosis of 
breast disease
6. Pathology (cytological and histological non-operative  procedures; 
open biopsy and resection specimens)
7. Surgery
8. Data collection and monitoring
9. Specialist breast units
10. Training
11. Certification of breast screening and diagnostic services
12. Breast screening communication Table III
screening process in Breast cancer
1. Information and invitation of eligible target population
2. Performance of screening test
3. Assessment of women with suspicious test results
4. Pre-operative diagnosis of screen-detected lesions
5. Treatment of women with screen-detected cancer
Figure 3. european guidelines For quality assurance 
in Breast cancer screening and diagnosis. Fourth 
edition12
population. It has already been pointed out that breast 
cancer can only be detected in a very small proportion of 
women attending any given round of screening. There-
fore only a relatively small number of women can have 
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This approach is essential in order to maximize ben-
efit, by making screening accessible to those in the 
population who are generally less likely to consume 
health resources of their own accord and in order to 
adequately monitor, evaluate and continuously improve 
performance.11,12,21 
Programme organisation
Another fundamental aspect is the programme ap-
proach to implementation of cancer screening (table 
IV). In many countries around the world, breast cancer 
screening is delivered in a variety of ways, ranging 
from highly organized programmes to “opportunistic” 
activities that involve referral to mammography facili-
ties by clinicians and self-referral by women themselves. 
Organized programmes are recommended because 
they include an administrative structure responsible for 
implementation, quality assurance and evaluation. The 
population-based, programme approach to implemen-
tation of screening services generally requires a high 
degree of organization in order to reliably identify and 
invite each eligible woman to attend screening. The pop-
ulation-based approach is also recommended because 
it provides an organisational framework conducive to 
effective management of performance, and continuous 
improvement of the screening process, such as through 
linkage with population and cancer registries for opti-
misation of invitation to screening and for evaluation of 
screening performance and impact.2,11-14,20,21
Programme management
Of special relevance to any discussion on implementa-
tion of screening programmes of appropriate quality is 
the importance of autonomy of programme manage-
ment in the internal operation and administration of 
the screening programme.22 Any publically mandated 
health programme requires oversight and accountability 
in administrative, financial and clinical matters. But to 
effectively manage the quality of the screening service, 
senior management must be able to manage the way 
the available human and financial resources are used 
without undue external interference. Senior manage-
ment also must be held accountable for overall quality 
and performance of the programme. It is therefore im-
portant to appoint professionals and staff responsible for 
continuously monitoring quality assurance procedures, 
protocols and standards and reporting problems at an 
early stage so that programme management can respond 
effectively to potential problems and can provide ad-
equate support to develop new solutions, if needed. In 
essence, the organisation must be quality-driven, i.e., 
continuously striving to improve quality and perfor-
mance by setting targets, auditing and revising policies 
and procedures, if necessary, based on scientific methods 
and principles of best practice.11-13,22,23
 At the local or regional level, the professional head 
of a screening unit must also have the appropriate au-
thority and means to maintain standards and outcomes. 
If necessary, suspension of inadequate elements of the 
screening service must be possible, until delivery of ser-
vices of appropriate quality can be guaranteed.11,12,23
 Further key requirements for effective quality 
assurance of breast cancer screening are mentioned 
in tables IV and V. All of these elements are of special 
importance. In the available space, the attention of the 
reader is drawn to the following aspects.
Communication
Women invited to attend screening must receive objec-
tive, balanced information that enables them to make an 
informed decision on whether or not to attend screening. 
This is an important aspect that has been recognized 
very early in the development of the EU Guidelines.10-13 
Furthermore, women must receive sufficient and ap-
propriate information to be able to make an informed 
decision to participate in each subsequent step in the 
Table IV
quality assurance in Breast cancer screening
Underlying concepts
•	 Screening	as	a	public	health	endeavour
•	 Comprehensive	process	of	screening
•	 Overriding	aim	of	minimising	harm	and	maximising	benefit
•	 Need	for	population-based	organisation	and	evaluation
•	 Standards	of	performance	and	procedures	of	best	practice
•	 Continuous	quality	improvement
Other key elements
•	 Programme	organisation	and	management
•	 Specialized	training	of	all	staff
•	 Observance	of	volume	levels	(e.g.	reading	5	000	Mx/year)
•	 Avoidance	of	mixing	screening	clients	and	patients
•	 Dedication	of	facilities	and	equipment	to	screening	service
•	 Multidisciplinary	team-working	(e.g.	pre-	and	post-operative
 conferences)
•	 Physico-technical	quality	control	of	equipment
•	 Comprehensive,	standardized	documentation	and	monitoring
•	 Professional	supervision
•	 Audit,	certification	and	evaluation
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screening process, and they must be able to withdraw 
consent to participate in screening at any point in the 
process, such as during diagnostic assessment of lesions 
detected in screening.
Specialization of staff and
dedication of facilities
Another overriding element essential to achieving and 
maintaining high quality in implementation of breast 
cancer screening programmes is the need for specializa-
tion of staff and dedication of services (table III). Spe-
cialization need not prevent many of the professionals 
engaged in breast cancer screening from pursuing other 
professional activities outside of dedicated screening 
units. However, screening of appropriate quality re-
quires substantial expertise, at every step in the process, 
for example in communication with women attending 
screening, or in reading screening films, or performing 
diagnostic work-up of lesions detected in screening. 
The requisite skills not only require specialized and 
continued training, but also high volumes of screen-
ing services performed by individual professionals in 
order to achieve sufficient throughput to maintain their 
special competence. Specialized training and dedicated 
facilities and organization are also of key importance in 
establishing adequate physico-technical quality control 
of equipment. Dedication of facilities also reduces un-
necessary anxiety by avoiding intermingling of healthy 
screening clients with symptomatic patients. 
 In some cases, such as in diagnostic assessment 
of women with abnormalities detected in screening, it 
may not be cost-effective to reserve all available facili-
ties in a diagnostic unit, for dealing with women who 
have attended the screening programme. In such cases, 
dedicated sessions can be scheduled in which a diag-
nostic unit is reserved for a team dealing entirely with 
assessment of women attending screening.
Multidisciplinary diagnosis and clinical 
management of breast lesions
Effective screening programmes require integration into 
a routine health care infrastructure capable of deliver-
ing high quality diagnosis and treatment. The scope of 
the fourth edition of the EU guidelines therefore also 
covers multidisciplinary diagnosis of symptomatic le-
sions, and requirements for specialist breast units for 
multidisciplinary management of both screen-detected 
and symptomatic breast cancers.
Performance parameters
Given the complexity of the screening process, a large 
number of organisational, professional and technical 
performance parameters must be continuously moni-
tored in order to recognize and respond to unfavourable 
trends before they can lead to inappropriate effects for 
women attending screening. For correct interpretation, 
data from various steps in the screening process should 
be monitored jointly, taking into account potential effects 
of changes in performance at one step in the process, on 
performance at other steps or in other sub-processes. In 
a Summary Table, 50 key parameters for monitoring 39 
items have been collated from the individual chapters 
of the EU guidelines.11,12 Monitoring, though essential, 
cannot substitute for the long-term evaluation of the 
impact of a screening programme on the burden of 
disease in the population.
Discussion
Substantial experience in implementation of cancer 
screening programmes for large segments of the adult 
female population currently exists in Europe due, to 
a large part, to the coordinated efforts in the Europe 
Against Cancer Programme that began in the late 1980s 
and continued for fifteen years. Those efforts included 
provision of technical and scientific support for plan-
ning and piloting and for exchanging information and 
experience in population-based breast and cervical 
cancer screening programmes in the EU Member States. 
The need to explain the fundamental standards and 
principles of best practice that a screening programme 
of appropriate quality must achieve became evident 
early in these efforts. For this purpose, the European 
Guidelines for quality assurance in breast and cervi-
cal cancer screening were developed. The EU breast 
screening Guidelines quickly became an internationally 
recognized reference for best practice in breast cancer 
screening and diagnosis and later also in multidisci-
Table V
selected speciFic requirements For quality assurance 
in Breast cancer
•	 Adequate	information	presented	in	an	appropriate,	unbiased	manner	
to allow fully informed choice on attendance
•	 Breast	care	nurse	on	core	multidisciplinary	team
•	 Independent	double	reading	of	screening	mammograms
•	 Standardization	of	pathology	procedures	and	reporting
•	 Comprehensive	professional	QA	protocols
•	 Nomination	of	professional	responsible	for	overall	unit	performance	
and with authority to maintain standards and outcomes by suspending 
inadequate elements, if necessary
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plinary management of breast cancer; the guidelines 
have been repeatedly updated and expanded since the 
publication of the first edition by the European Com-
mission in 1993.17 The scope and the principles of qual-
ity assurance and best practice anchored in the current 
edition of the EU breast cancer screening guidelines 
have served as a model for the new EU Guidelines for 
quality assurance in colorectal cancer screening and 
diagnosis.19,20 
Gold standard for breast cancer screening
The availability of the regularly expanded and updated 
European quality assurance guidelines since 1993 has 
created a “gold standard” for breast cancer screening 
programmes, even though the European Commis-
sion does not have a legal mandate to enforce their 
implementation. It is currently unlikely, for example, 
that mammography equipment that does not fulfill the 
standards recommended in the European Guidelines 
can be profitably marketed in Europe. So great is the 
recognition and acceptance of the EU Guidelines that 
manufacturers now attempt to outperform each other 
in compliance with the guidelines.
 The existence of a gold standard has substantially 
facilitated the process of commissioning national and re-
gional breast cancer screening programmes. In principle a 
government agency or a legislative body seeking to estab-
lish a breast cancer screening programme no longer has 
to describe in detail a programme of appropriate quality 
prior to officially mandating its implementation. Only key 
parameters such as the target population and age group, 
the test and the screening interval need to be specified in 
the official decision to establish a programme, provided 
the respective directive, law or parliament resolution also 
specifies that the standards and recommendations in the 
European Guidelines must be fulfilled.
 The experience in Europe shows that not only the 
quality of the process of screening, but also the quality of 
the process by which screening programmes are imple-
mented can be assured.22 Determinants of successful 
implementation of population-based cancer screening 
programmes have been developed that also apply to 
breast cancer screening.23
Council Recommendation on Cancer 
Screening
In 2003, based on the positive experience in the Europe 
Against Cancer Programme, the Council of the Euro-
pean Union, that is the highest governing body in the 
EU, recommended implementation of population-based 
breast, cervical and colorectal cancer screening pro-
grammes, using evidence-based methods and following 
the EU Guidelines for quality assurance in breast and 
cervical cancer screening (colorectal cancer screening 
guidelines were not yet developed at the time). The 
unanimous adoption of the Council Recommendation 
on Cancer Screening of 2 December 200324 by the Health 
Ministers of the EU underlined the importance of the 
principles and procedures of best practice in the EU 
quality assurance guidelines for cancer screening and 
substantially facilitated their implementation by the EU 
Member States. By the end of 2007 population-based 
programmes for breast cancer screening were running 
or being established in 22 of the 27 EU Member States. 
In 11 Member States rollout of the population-based 
breast screening programme across the entire country 
was already complete. In the other 11 Member states 
establishing population-based breast cancer screening, 
rollout had already begun in seven Member States; 
four other Member States were still in the publically 
mandated planning and/or piloting phase.21,25
Translational phase of programme 
implementation
In 2008, the European Commission published the first re-
port on implementation of the Council Recommendation 
on Cancer Screening.21 A key conclusion of the report 
was that a long-term translational phase is essential to 
successfully plan, pilot and rollout population-based 
cancer screening programmes across an entire country, 
and particularly also across several countries. The time 
frame depends, to a large extent, on the professional 
and organisational capacity that must be developed 
to successfully perform, monitor and evaluate high 
quality services integrating all steps in the screening 
process. This activity not only entails coordination of 
complex communication and training, but also integra-
tion of multidisciplinary teams into the diagnosis and 
treatment of screen-detected lesions, and integration of 
cancer registration and cancer registries into the moni-
toring and evaluation of programme performance. Even 
in countries with relatively small target populations, the 
magnitude of the task can be substantial, compared to 
initially available resources. Successful preparation and 
completion of the nationwide implementation process 
may require ten years or more.21,22
Process of quality-assured programme 
development
The experience in Europe also demonstrates the im-
portance of international collaboration during the 
translational phase of establishing a population-based 
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cancer screening programme. International collabora-
tion can compensate for the relative shortage of expertise 
in any given country embarking on this complex and 
protracted journey. Collaboration can not only improve 
results, it can also avoid unnecessary delays in establish-
ing fully functional screening programmes.21-23
 Table VI provides an overview of the key steps 
in the process of quality-assured implementation of 
a population-based screening programme.22,23 Profes-
sionals experienced in establishing population-based 
programmes and providing high quality screening, 
diagnostic and therapeutic services are not only needed 
to check the adequacy of preparations prior to piloting 
(phase 3) or before transition of a pilot to service screen-
ing (phase 5). The accumulated experience in Europe 
shows that international collaboration in specialized 
training of staff, in the procurement, installation and 
technical quality assurance of equipment, as well as in 
development and continuous improvement of documen-
tation and monitoring systems and particularly also in 
coaching the professionals managing and providing the 
screening services can avoid common pitfalls and can 
substantially improve the quality and accelerate the pace 
in every phase of programme implementation.21-23
Impact of implementation of a population-
based breast cancer screening programme 
on symptomatic (usual) care
Another key conclusion in the first report on imple-
mentation of the Council Recommendation on Cancer 
Screening21 deals with the potential impact of establish-
ing population-based cancer screening programmes 
on the quality and effectiveness of symptomatic, i.e., 
usual care. Implementation of screening programmes 
of high quality has the potential to not only lower the 
burden of disease in the people attending screening. 
That is the primary goal and benchmark of success of 
any screening programme.11-13 However, it should be 
kept in mind that the protracted process of establishing 
a population-based breast cancer screening programme 
of high quality also has the potential to substantially im-
prove the overall level of breast cancer care in a country, 
because large numbers of professionals undertake ad-
ditional training to meet the high screening standards. 
Furthermore, in regions and communities all over the 
country, the same professionals are also involved in di-
agnosis and treatment of cancer detected outside of the 
screening programme. Moreover, new or improved mul-
tidisciplinary standards and procedures of diagnosis are 
developed and tested in the early phases of programme 
planning, feasibility testing and piloting. Thus, the same 
high standards of diagnosis and treatment that are de-
veloped, piloted and rolled out across a country when 
a nationwide population-based screening programme is 
established, will be widely used in provision of symp-
tomatic care. The resulting widespread improvements 
in the quality and effectiveness of symptomatic breast 
care contribute substantially to the positive impact of 
population-based screening programmes on the overall 
control of breast cancer. This positive development ap-
plies also to screening for other chronic disease, such as 
cervical and colorectal cancer.14,21,22
Accreditation of specialist breast units 
In 2008, the Council of the EU adopted conclusions on 
reducing the burden of cancer in the EU in which the 
experience in implementation of the Council Recom-
mendation on Cancer Screening was taken into ac-
count.26 Among other things, the Council encouraged 
the European Commission to ensure medium- and 
long-term scientific and professional support to Mem-
ber States in implementation of the Council Recom-
mendation on Cancer Screening. It also encouraged 
the European Commission to explore the potential of 
implementing another recommendation in the above 
report, namely, the development of a European pilot 
accreditation scheme for breast cancer screening and 
follow-up based on the European guidelines for quality 
assurance in breast cancer screening and diagnosis. The 
project has been included in the 2010 work plan of the 
EU Health Programme with the aims of developing a 
tool that will: 1) enable women to recognize that breast 
units meet the European quality assurance standards, 
2) assist the Member States in ensuring that quality 
standards are met, and 3) encourage continuous quality 
improvement in breast cancer care throughout the EU. 
The project will concentrate initially on accreditation of 
multidisciplinary diagnostic and therapeutic services 
Table VI
sequence oF steps in quality-assured screening 
programme implementation in Breast cancer
1. Comprehensive planning of screening process
2. Preparation of all components of screening process and QA to per-
form at requisite high level (feasibility testing, training, organisation)
3. Expert verification of adequacy of preparations
4. Pilot testing and modification, if necessary, of all screening systems 
and components, including QA 
5. Expert verification of adequacy of pilot performance
6. Transition of pilot to service screening and geographically phased 
programme rollout in other regions of the country
7. Intensive monitoring of programme rollout for early detectionand 
correction of quality problems
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in specialist breast units. A key focus in piloting the ac-
creditation protocol will be on providing appropriate 
support to breast centers in Member States interested in 
learning how to achieve the accreditation standards.
Outlook
Supplements to the fourth edition of the European 
Guidelines for Quality Assurance in Breast Cancer 
Screening and Diagnosis have been developed in recent 
years. They include updates on quality assurance in pa-
thology and an updated European protocol on physico-
technical aspects of quality control, as well as a protocol 
for type testing of digital mammography equipment. 
Preparations are also underway for development of a 
completely revised 5th edition of the European Guide-
lines. The new 5th edition will include additional new 
chapters, such as one on breast care nursing. 
Conclusions
Implementation of breast cancer screening programmes 
is a public health endeavor that aims to lower the burden 
of the disease in the population. To achieve the potential 
benefit of breast cancer screening, quality must be optimal 
at every step in the screening process that begins with in-
formation and invitation of the eligible target population 
and includes performance of the screening test, diagnostic 
assessment of abnormalities detected in screening and, if 
necessary, treatment and aftercare. This requires signifi-
cant sustainable resources for quality assurance.
 In a collaborative international network focused on 
the Member States of the European Union, comprehensive 
guidelines for quality assurance in breast cancer screening 
have been developed and continuously updated over the 
past two decades. The existence of this gold standard has 
facilitated the commissioning of programmes of appropri-
ate quality in over 20 European countries.
 Implementation of breast cancer screening in 
the organizational framework of population-based 
programmes is recommended because organized 
programmes include an administrative structure re-
sponsible for implementation, quality assurance and 
evaluation. The population-based approach gener-
ally requires a high degree of organization in order 
to reliably identify and invite each eligible woman to 
attend screening. This alleviates health inequalities and 
provides an organisational framework conducive to 
effective management of performance, evaluation, and 
continuous improvement of the screening process.
 The experience in Europe also demonstrates 
that the quality of the lengthy process of establishing 
population-based breast cancer screening programmes 
can also be assured. International collaboration and 
exchange of experience during the translational phase 
of planning, piloting and rolling out a population-based 
screening programme can avoid common pitfalls and 
can improve the pace and the outcome of programme 
implementation.
 During this period, specialized training of personnel 
and development and testing of improved diagnostic 
and treatment protocols has the potential to also improve 
the quality and effectiveness of symptomatic breast can-
cer care, and to thereby also improve control of breast 
cancer detected outside of the screening programme.
 The potential positive impact of population-based 
breast cancer screening on symptomatic care should be 
taken into account in the evaluation of any breast cancer 
screening programme.
 The European experience of promoting imple-
mentation of population-based breast cancer screening 
programmes through international collaboration in de-
velopment and implementation of common standards, 
principles and protocols of best practice may be a model 
for other countries and regions in which the burden of 
breast cancer in the coming years will make population-
based screening an option for improving control of the 
disease. 
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